本頁面由Tiger Trade Technology Pte. Ltd.提供服務

ArcBest Corporation

128.95
-1.0200-0.78%
盤後128.950.00000.00%17:43 EDT
成交量:32.65萬
成交額:4,246.74萬
市值:28.82億
市盈率:179.57
高:133.01
開:132.09
低:128.77
收:129.97
52周最高:176.69
52周最低:59.43
股本:2,234.95萬
流通股本:2,193.77萬
量比:1.37
換手率:1.49%
股息:0.48
股息率:0.37%
每股收益(TTM):0.7181
每股收益(LYR):2.63
淨資產收益率:1.27%
總資產收益率:2.81%
市淨率:2.27
市盈率(LYR):49.00

資料載入中...

2020/05/01

重要事件披露

Current report, items 8.01 and 9.01
2020/04/28

重要事件披露

Current report, item 5.02
2020/04/07

重要事件披露

8-K - Current report
2020/03/30

重要事件披露

Current report, items 2.03 and 7.01
2020/02/28

年度報告

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2020/02/12

超過5%披露

[Amend] Statement of acquisition of beneficial ownership by individuals
2020/02/11

超過5%披露

[Amend] Statement of acquisition of beneficial ownership by individuals
2020/02/06

員工持股計劃

Securities to be offered to employees in employee benefit plans, post-effective amendments
2020/02/06

員工持股計劃

Securities to be offered to employees in employee benefit plans, post-effective amendments
2020/02/06

員工持股計劃

Securities to be offered to employees in employee benefit plans, post-effective amendments
2020/02/06

員工持股計劃

Securities to be offered to employees in employee benefit plans, post-effective amendments
2020/02/06

員工持股計劃

Securities to be offered to employees in employee benefit plans, post-effective amendments
2020/02/06

員工持股計劃

Securities to be offered to employees in employee benefit plans, post-effective amendments
2020/02/06

員工持股計劃

Securities to be offered to employees in employee benefit plans, post-effective amendments
2020/02/06

員工持股計劃

Securities to be offered to employees in employee benefit plans, post-effective amendments
2020/02/04

超過5%披露

[Amend] Statement of acquisition of beneficial ownership by individuals
2020/01/30

重要事件披露

Current report, items 2.02 and 9.01
2020/01/28

重要事件披露

Current report, items 8.01 and 9.01
2020/01/08

超過5%披露

[Amend] Statement of acquisition of beneficial ownership by individuals
2019/12/16

重要事件披露

Current report, items 7.01 and 8.01